Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

PARDDelisted Stock  USD 0.01  0.00  0.00%   
About 56% of Poniard Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Poniard Pharmaceuticals pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Poniard Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Poniard Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Poniard Pharmaceuticals pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Poniard daily returns and investor perception about the current price of Poniard Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios.
  
Vir Biotechnology, Inc. today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of

Read at businesswire.com
businesswire News
  

Poniard Pharmaceuticals Fundamental Analysis

We analyze Poniard Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Poniard Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Poniard Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Debt To Equity

Debt To Equity Comparative Analysis

Poniard Pharmaceuticals is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Poniard Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Poniard Pharmaceuticals pink sheet to make a market-neutral strategy. Peer analysis of Poniard Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Poniard Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Poniard Pharmaceuticals Related Equities

XLOXilio Development   7.92   
0%
100.0%
SRRKScholar Rock   4.59   
0%
57.0%
ADPTAdaptive Biotechnologies   3.66   
0%
46.0%
IKNAIkena Oncology   2.37   
0%
29.0%
VIRVir Biotechnology   1.27   
0%
16.0%
BCYCBicycle Therapeutics   0.25   
0%
3.0%
APLSApellis Pharmaceuticals   0.62   
7.0%
0%
CYTKCytokinetics   0.69   
8.0%
0%
CRNXCrinetics Pharmaceuticals   0.81   
10.0%
0%
TARAProtara Therapeutics   0.99   
12.0%
0%
LEGNLegend Biotech   2.46   
31.0%
0%
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Consideration for investing in Poniard Pink Sheet

If you are still planning to invest in Poniard Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Poniard Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules